Ospedale "A. Perrino"
- Address
- Strada Statale 7 (APPIA), 72100 Brindisi, Italy
Ospedale A. Perrino - Advanced Oncology Research Center
Ospedale A. Perrino is a distinguished clinical research institution specializing in innovative cancer treatments and targeted therapies. The center demonstrates particular expertise in precision oncology, conducting cutting-edge trials that evaluate biomarker-driven therapeutic strategies and novel combination treatments across multiple tumor types. Their research portfolio reflects a commitment to advancing personalized medicine approaches in oncology.
- Advanced breast cancer research, including hormone receptor-positive and HER2-negative tumors with focus on CDK4/6 inhibitor combinations and neoadjuvant therapies
- Non-small cell lung cancer (NSCLC) trials investigating EGFR-mutated disease and PD-L1 high tumors with immunotherapy and targeted agent combinations
- Gastrointestinal malignancies including metastatic colorectal cancer with RAS/BRAF biomarker-guided cetuximab regimens
- Head and neck cancers, specifically oral cavity and oropharyngeal squamous cell carcinoma utilizing electrochemotherapy techniques
The center's research extends beyond traditional oncology to include critical care medicine, as evidenced by their participation in the VICToRY trial examining high-dose intravenous vitamin C therapy for severe burn injury management. Additionally, Ospedale A. Perrino contributes to gynecologic oncology research, particularly in BRCA wild-type ovarian cancer maintenance therapy strategies using PARP inhibitors. This diverse research portfolio positions the institution at the forefront of translational medicine and evidence-based therapeutic development.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 21 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ospedale "A. Perrino"
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Cetuximab-Based Regimen in RAS/BRAF Wild-Type Metastatic Colorectal Cancer with Trifluridine/Tipiracil and Drug Combination | Gruppo Oncologico Dell'Italia Meridionale | Phase II | Recruiting | Jul 2021 | — |
IMP list
lock Showing 1 of 21 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bevacizumab | 3 | Unknown | 2015-11-23 | 2021-07-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.